HLA-B*1502 & B2M Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| IPP-204106 | N6L; Nucant-6L; IPP-204106; IPP-204106N; poyplexed IPP-204106 | Phase 2 Clinical | Immupharma Plc | Solid tumours; Neoplasms | Details |
| AS-1411 | AGRO-100; GR-026-B; AS-1411; ACT-GRO-777 | Phase 2 Clinical | University Of Louisville, Antisoma, University Of Alabama At Birmingham | Solid tumours; Neoplasms | Details |
| Pegylated recombinant human endostatin (Tsinghua University) | M-2ES; CRB-0401 | Phase 1 Clinical | Tsinghua University, Beijing Protgen Biotechnology Development Co Ltd, Beijing Proji Pharmaceutical Technology Co Ltd | Solid tumours; Pancreatic Neoplasms; Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| APTA-16 | APTA-16; SJP1604 | Phase 1 Clinical | Aptabio Therapeutics Inc | Liver Neoplasms; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Recombinant human endostatin (Simcere) | YH-16 | Approved | Jiangsu Simcere Pharmaceutical Co Ltd | Endostar, 恩度, Endu | Mainland China | Carcinoma, Non-Small-Cell Lung | Shandong Simcere Bio-Pharmaceutical Co Ltd | 2005-09-12 | Head and Neck Neoplasms; Esophageal Neoplasms; Ascites; Osteosarcoma; Nasopharyngeal Carcinoma; Brain metastases; Pleural Effusion, Malignant; Carcinoma, Non-Small-Cell Lung | Details |